SCHEMBL3013682

SCHEMBL3013682

O=S(=O)(c1ccc(CBr)cc1)N1CCN(c2nc(-c3ccc(Cl)c(F)c3)cs2)CC1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.63
ALDH1A1 P00352 5/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MAPT P10636 5/20 0.54
USP2 O75604 1/20 0.54
RECQL P46063 1/20 0.54
HSD17B10 Q99714 1/20 0.54
MAPK1 P28482 4/20 0.48
LMNA P02545 5/20 0.46
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
AR P10275 1/20 0.45
POLB P06746 1/20 0.42
RAB9A P51151 2/20 0.41
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
THRB P10828 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008731 0.93 SMN1; SMN2 (0.63) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3004649 0.92 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3019676 0.91 SMN1; SMN2 (0.61) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3010820 0.90 SMN1; SMN2 (0.68) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3016696 0.89 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3018178 0.89 SMN1; SMN2 (0.80) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3649330 0.88 SMN1; SMN2 (0.63) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3010149 0.87 ALDH1A1 (0.67) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3018617 0.87 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2
SCHEMBL3005614 0.87 SMN1; SMN2 (0.66) SMN1; SMN2ALDH1A1L3MBTL1MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885ALDH1A1 3510/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.